AbbVie Inc. is 96.3x more valuable than Tango Therapeutics, Inc. by market capitalization ($399.47 B vs $4.15 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | TNGX | ABBV |
|---|---|---|
| Market cap | $4.15 B | $399.47 B |
| US-listed rank | #1540 | #28 |
| Revenue (latest FY) | $62.38M | $61.16B |
| Net income (latest FY) | -$101.60M | $4.23B |
| Net margin | -162.9% | 6.9% |
| P/E (trailing FY) | - | 94.5 |
| SEC filings | 382 | 1,008 |
AbbVie Inc. is 96.3x more valuable than Tango Therapeutics, Inc. by market capitalization ($399.47 B vs $4.15 B).
In their latest fiscal years, Tango Therapeutics, Inc. reported $62.38M in revenue while AbbVie Inc. reported $61.16B.
Full pages: Tango Therapeutics, Inc. and AbbVie Inc., or browse the full rankings.